Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cellectis S.A. (CLLS) vs Rani Therapeutics Holdings, Inc. (RANI)

Cellectis S.A. and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Cellectis S.A. and Rani Therapeutics Holdings, Inc. are of similar size ($107.3M and $103.4M). Rani Therapeutics Holdings, Inc. grew revenue faster over the last twelve months: 78.7% against 0.61%. Cellectis S.A. has the higher net margin (−102.3% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Rani Therapeutics Holdings, Inc. leads on 8 and Cellectis S.A. on 7.

Valuation

Metric CLLS RANI Biotechnology median
P/E n/m n/m 7.88
P/S 2.32 28.17 11.47
P/B 3.60 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.86 20.72 10.73
Earnings yield (44.50%) (35.53%) (28.84%)
Free cash flow yield (31.23%) (14.30%) (23.03%)

Profitability

Metric CLLS RANI Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (90.88%) (652.78%) 0.00%
Net margin (102.34%) (596.97%) 0.00%
Free cash flow margin (68.63%) (402.83%) 0.00%
Return on equity (94.54%) (155.24%) (57.72%)
Return on assets (21.02%) (77.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS RANI Biotechnology median
Revenue growth (TTM) 0.61% 78.73% 5.64%
EPS growth (last fiscal year) (63.41%) 57.14% —
Revenue growth, 5-year CAGR (0.70%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS RANI Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 5.31 4.73
Net debt to EBITDA 9.54 1.33 0.96

Dividend

Metric CLLS RANI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLLS RANI Biotechnology median
Market cap 103.43m 107.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack